Balance Sheet
Accounts PayablesAccumulated ExpensesAssetsCash & Current InvestmentsCash & EquivalentsCommon EquityCurrent AssetsGoodwill & IntangiblesIntangiblesLiabilities and Shareholders EquityNon-Current AssetsOther Accumulated ExpensesOther Non-Current AssetsOther Non-Current LiabilitiesPayablesPrepaid AssetsProperty, Plant & Equipment (Net)ReceivablesRetained EarningsShareholder's EquityShares OutstandingTotal Current LiabilitiesTotal LiabilitiesTotal Non-Current Liabilities
Cash Flow Statement
Daily Values
Growth Metrics
Income Statement
Others
Ratios

Traws Pharma (TRAW) Accumulated Expenses (2016 - 2025)

Traws Pharma's Accumulated Expenses history spans 14 years, with the latest figure at $4.3 million for Q4 2025.

  • Quarterly results put Accumulated Expenses at $4.3 million for Q4 2025, up 36.85% from a year ago — trailing twelve months through Dec 2025 was $4.3 million (up 36.85% YoY), and the annual figure for FY2025 was $4.3 million, up 36.85%.
  • Accumulated Expenses for Q4 2025 was $4.3 million at Traws Pharma, up from $774000.0 in the prior quarter.
  • In the past five years, Accumulated Expenses ranged from a high of $4.3 million in Q4 2025 to a low of $502000.0 in Q2 2025.
  • The 5-year median for Accumulated Expenses is $2.6 million (2022), against an average of $2.4 million.
  • The sharpest move saw Accumulated Expenses surged 227.06% in 2023, then tumbled 82.48% in 2024.
  • Year by year, Accumulated Expenses stood at $3.1 million in 2021, then dropped by 17.21% to $2.6 million in 2022, then soared by 30.16% to $3.4 million in 2023, then decreased by 7.53% to $3.1 million in 2024, then surged by 36.85% to $4.3 million in 2025.
  • According to Business Quant data, Accumulated Expenses over the past three periods came in at $4.3 million, $774000.0, and $502000.0 for Q4 2025, Q3 2025, and Q2 2025 respectively.